SAN FRANCISCO--(BUSINESS WIRE)--FibroGen, Inc. today announced that new research on its therapeutic development programs in kidney disease involving connective tissue growth factor (anti-CTGF) and hypoxia inducible factor (HIF) prolyl hydroxylase inhibitors (PHI) was reported at the 42nd annual meeting of the American Society of Nephrology (ASN) Renal Week October 27-November 1, 2009, in San Diego, California.
